Gene · 249
Papers3,295
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,295
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| EGCG and Taxifolin Modulate Secretory Activity and Expression of Dentinogenesis Markers in Odontoblast-Like Cells. | Scientifica (Cairo) | 2025 | 40225282 | PubTator, text mining | PubMed |
| Family mapping of previously identified patients with pathogenic or likely pathogenic ALPL variants using predictive genotyping and detailed phenotyping approach: the FAME case-control study. | JBMR Plus | 2025 | 40224914 | PubTator, text mining | PubMed |
| Effects of enzyme replacement therapy in sibling cases of hypophosphatasia of varying severities. | Clin Pediatr Endocrinol | 2025 | 40201376 | PubTator, text mining | PubMed |
| Pathogenic variants prevalence patients with diabetic kidney disease in Japan: A descriptive study. | J Diabetes Investig | 2025 | 40197820 | PubTator, text mining | PubMed |
| Effects of asfotase alfa on fracture healing of adult patient with hypophosphatasia and literature review. | Orphanet J Rare Dis | 2025 | 40189581 | PubTator, text mining | PubMed |
| Selective effects of collagen-derived peptides Pro-Hyp and Hyp-Gly on the proliferation and differentiation of SSEA3-positive human dental pulp stem cells. | Regen Ther | 2025 | 40170801 | PubTator, text mining | PubMed |
| LincRNA-ASAO promotes dental pulp repair through interacting with PTBP1 to increase ALPL alternative splicing. | Stem Cell Res Ther | 2025 | 40140936 | PubTator, text mining | PubMed |
| Safety and efficacy of long term asfotase alfa treatment in childhood hypophosphatasia. | Ital J Pediatr | 2025 | 40114282 | PubTator, text mining | PubMed |
| Medical Management of Hypophosphatasia: Review of Data on Asfotase Alfa. | Curr Osteoporos Rep | 2025 | 40100438 | PubTator, text mining | PubMed |
| Hypophosphatasia: the importance of knowing in advance. | Minerva Endocrinol (Torino) | 2025 | 40067753 | PubTator, text mining | PubMed |
| Long-Term Outcomes of Early Enzyme Replacement Therapy With Asfotase Alfa in Perinatal Benign Hypophosphatasia: Amelioration of Bone Deformities in a Young Child. | Cureus | 2025 | 40051960 | PubTator, text mining | PubMed |
| Potential of MSCA1 for isolating osteogenic cells in a chondrocyte population. | Sci Rep | 2025 | 40050298 | PubTator, text mining | PubMed |
| Diagnosis and Treatment of Hypophosphatasia. | Calcif Tissue Int | 2025 | 40047955 | PubTator, text mining | PubMed |
| Sequential prenatal diagnosis of fetal skeletal dysplasia: A cohort study. | Acta Obstet Gynecol Scand | 2025 | 40035361 | PubTator, text mining | PubMed |
| Editorial commentary to CASR, CLDN 14, ALPL & SLC34A1 genes are associated with the risk of nephrolithiasis in Egyptian children. | J Pediatr Urol | 2025 | 40023701 | PubTator, text mining | PubMed |
| Genetic characterization of a large cohort of individuals with a clinical suspicion of hypophosphatasia in the United States. | Mol Genet Metab | 2025 | 39983296 | PubTator, text mining | PubMed |
| Pharmacological mechanisms of carvacrol against hepatocellular carcinoma by network pharmacology and molecular docking. | Technol Health Care | 2025 | 39973856 | PubTator, text mining | PubMed |
| Disease burden by ALPL variant number in patients with non-life-threatening hypophosphatasia in the Global HPP Registry. | J Med Genet | 2025 | 39965917 | PubTator, text mining | PubMed |
| Circulating Micro-RNAs in Patients With Hypophosphatasia: Results of the First Micro-RNA Analysis in HPP. | J Clin Endocrinol Metab | 2025 | 39930630 | PubTator, text mining | PubMed |
| High Prevalence of Nephrocalcinosis in Hypophosphatasia Patients with the ALPL c.1559del Gene Variant. | JMA J | 2025 | 39926094 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/249/papers?page=10